GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » PB Ratio

Glaukos (Glaukos) PB Ratio : 12.06 (As of May. 10, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-10), Glaukos's share price is $109.025. Glaukos's Book Value per Share for the quarter that ended in Mar. 2024 was $9.04. Hence, Glaukos's PB Ratio of today is 12.06.

The historical rank and industry rank for Glaukos's PB Ratio or its related term are showing as below:

GKOS' s PB Ratio Range Over the Past 10 Years
Min: 1.65   Med: 7.41   Max: 135.27
Current: 12.06

During the past 11 years, Glaukos's highest PB Ratio was 135.27. The lowest was 1.65. And the median was 7.41.

GKOS's PB Ratio is ranked worse than
94.95% of 792 companies
in the Medical Devices & Instruments industry
Industry Median: 2.25 vs GKOS: 12.06

During the past 12 months, Glaukos's average Book Value Per Share Growth Rate was -14.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -13.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 6.40% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Glaukos was 64.80% per year. The lowest was -13.90% per year. And the median was 27.50% per year.

Back to Basics: PB Ratio


Glaukos PB Ratio Historical Data

The historical data trend for Glaukos's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos PB Ratio Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.52 5.10 3.55 3.94 8.46

Glaukos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.72 7.05 7.68 8.46 10.43

Competitive Comparison of Glaukos's PB Ratio

For the Medical Devices subindustry, Glaukos's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's PB Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's PB Ratio falls into.



Glaukos PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Glaukos's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=109.025/9.042
=12.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Glaukos  (NYSE:GKOS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Glaukos PB Ratio Related Terms

Thank you for viewing the detailed overview of Glaukos's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (Glaukos) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Glaukos (Glaukos) Headlines

From GuruFocus

Glaukos Announces Participation in the Citi Healthcare Conference

By Business Wire Business Wire 02-15-2023

Glaukos Announces the Release of its 2022 Sustainability Report

By Business Wire Business Wire 04-19-2023

INTERWEST VENTURE MANAGEMENT CO's Top 5 Sells of the 4th Quarter

By GuruFocus Research GuruFocus Editor 01-31-2023

Should Investors Worry About Glaukos Corp's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-18-2023

Glaukos Corp Insider Sells Company Shares

By GuruFocus Research 01-19-2024

Insider Alert: An Insider Just Sold Glaukos Corp Shares

By GuruFocus Research GuruFocus Editor 05-19-2023